Myeloma 2022: day two highlights
VJHemOnc Podcast
00:00
The Importance of Combination Therapies and the Shift Towards Minimal Residual Disease
The chapter discusses the significance of combining therapies in the treatment of myeloma, emphasizing the early introduction of effective therapies and the use of bi-specifics and CAR T cells. It highlights the shift towards using different therapies to achieve deep responses, particularly focusing on minimal residual disease as an endpoint.
Transcript
Play full episode
